Author Year Country Study design Sex Participants’ disease Colchicine dosage Control Age, years (intervention/control) Duration of colchicine usage Duration of follow-up Sample size, Endpoint (s) Mariama Akodad [32 ] 2016 France Clinical trial Both STEMI Colchicine 1 mg daily+optimal medical care Optimal medical care alone 60.1/59.7 1 month 1 month 23/21 CRP, all-cause mortality, GI adverse events Thomas Hennessy [33 ] 2019 Australia RCT Both Acute MI 0.5 mg daily Placebo 61/61 1 month 1 month 119/118 hs-CRP, all-cause mortality, MI, GI adverse events Nina C. Raju [34 ] 2011 Australia RCT Both ACS or ischemic stroke 1 mg daily Placebo 57.2/57.2 1 month 1 month 36/38 Hs-CRP, all-cause mortality, stroke, MI, GI adverse events Spyridon Deftereos [35 ] 2015 Greece RCT Both STEMI Loading dose of 2 mg continuing with 0.5 mg bid (if Placebo 58/58 5 days 5 days 77/74 hs-CRP, GI adverse events Jean-Claude Tardif [36 ] 2019 Multinational RCT Both MI 0.5 mg daily Placebo 62.1/61.2 19.6 and 19.5 months in colchicine and placebo groups, respectively (median) Median of 22.6 months overall and 6 months in hs-CRP substudy 2366/2379 overall and 99/108 in hs-CRP substudy All-cause mortality, stroke, MI, GI adverse events Trisulo Wasyanto [12 ] 2018 Indonesia RCT Both Acute MI 0.5 mg daily Placebo 57.8/52.8 5 days 5 days 16/16 hs-CRP David C. Tong [19 ] 2020 Australia RCT Both ACS 0.5 mg colchicine bid for the first month, followed by 0.5 mg daily for eleven months Placebo 59.7/60.0 12 months 365 days 396/399 All-cause mortality, stroke, MI, GI adverse events
